- Home
- ANGO vs XFOR Comparison
ANGO vs XFOR Comparison
Compare ANGO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | XFOR |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 377.3M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANGO | XFOR |
|---|---|---|
| Price | $13.31 | $4.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.00 | $9.00 |
| AVG Volume (30 Days) | 326.7K | ★ 469.4K |
| Earning Date | 04-02-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $8.36 | $1.35 |
| 52 Week High | $13.99 | $4.83 |
Technical Indicators
Market Signals| Indicator | ANGO | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 50.79 |
| Support Level | $13.02 | $3.58 |
| Resistance Level | $13.37 | $4.09 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 77.63 | 50.98 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.